Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Academic Article


  • BACKGROUND: Ivacaftor improves outcomes in cystic fibrosis (CF) patients with the G551D mutation; however, effects on respiratory microbiology are largely unknown. This study examines changes in CF respiratory pathogens with ivacaftor and correlates them with baseline characteristics and clinical response. METHODS: The G551D Observational Study enrolled a longitudinal observational cohort of US patients with CF aged 6 years and older with at least 1 copy of the G551D mutation. Results were linked with retrospective and prospective culture data in the US Cystic Fibrosis Foundation's National Patient Registry. Pseudomonas aeruginosa infection category in the year before and year after ivacaftor was compared and correlated with clinical findings. RESULTS: Among 151 participants prescribed ivacaftor, 29% (26/89) who were culture positive for P. aeruginosa the year prior to ivacaftor use were culture negative the year following treatment; 88% (52/59) of those P. aeruginosa free remained uninfected. The odds of P. aeruginosa positivity in the year after ivacaftor compared with the year prior were reduced by 35% (odds ratio [OR], 0.65; P < .001). Ivacaftor was also associated with reduced odds of mucoid P. aeruginosa (OR, 0.77; P = .013) and Aspergillus (OR, 0.47; P = .039), but not Staphylococcus aureus or other common CF pathogens. Patients with intermittent culture positivity and higher forced expiratory volume in 1 second (FEV1) were most likely to turn culture negative. Reduction in P. aeruginosa was not associated with change in FEV1, body mass index, or hospitalizations. CONCLUSIONS: Pseudomonas aeruginosa culture positivity was significantly reduced following ivacaftor treatment. Efficacious CFTR modulation may contribute to lower frequency of culture positivity for P. aeruginosa and other respiratory pathogens, particularly in patients with less established disease.
  • Authors

    Published In


  • CFTR modulator, P. aeruginosa, cystic fibrosis, ivacaftor, Adolescent, Adult, Aged, Aged, 80 and over, Amino Acid Substitution, Aminophenols, Aspergillus, Child, Cohort Studies, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Enzyme Activators, Female, Humans, Longitudinal Studies, Male, Middle Aged, Mutant Proteins, Mutation, Missense, Prevalence, Pseudomonas Infections, Pseudomonas aeruginosa, Quinolones, Staphylococcus aureus, Treatment Outcome, United States, Young Adult
  • Digital Object Identifier (doi)

    Author List

  • Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
  • Start Page

  • 703
  • End Page

  • 712
  • Volume

  • 60
  • Issue

  • 5